MEDICINA
Departamento
University of Milan
Milán, ItaliaPublicaciones en colaboración con investigadores/as de University of Milan (38)
2024
-
Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee
eClinicalMedicine, Vol. 69
-
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplantation for Patients with Hodgkin Lymphoma: A Comparative Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
Transplantation and Cellular Therapy, Vol. 30, Núm. 2, pp. 210.e1-210.e14
-
Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia
American Journal of Hematology, Vol. 99, Núm. 4, pp. 586-595
2023
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations
Blood
-
Procalcitonin and C-reactive protein to rule out early bacterial coinfection in COVID-19 critically ill patients
Intensive Care Medicine, Vol. 49, Núm. 8, pp. 934-945
-
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 15, pp. 2827-2842
-
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial
The Lancet Haematology, Vol. 10, Núm. 10, pp. e813-e824
-
Unmet Clinical Needs and Management Recommendations for Blastic Plasmacytoid Dendritic Cell Neoplasm: A Consensus-based Position Paper from an Ad Hoc International Expert Panel
HemaSphere, Vol. 7, Núm. 3, pp. E841
2022
-
COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP
Blood Advances, Vol. 6, Núm. 7, pp. 2427-2433
-
Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial
American Journal of Hematology, Vol. 97, Núm. 4, pp. 481-490
-
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Blood, Vol. 140, Núm. 11, pp. 1200-1228
-
Novel genes and sex differences in COVID-19 severity
Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806
-
Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma
Blood Advances
2021
-
2021 European myeloma network review and consensus statement on smoldering multiple myeloma: How to distinguish (and manage) Dr. Jekyll and Mr. Hyde
Haematologica, Vol. 106, Núm. 11, pp. 2799-2812
-
A generic emergency protocol for patients with inborn errors of metabolism causing fasting intolerance: A retrospective, single-center study and the generation of www.emergencyprotocol.net
Journal of Inherited Metabolic Disease, Vol. 44, Núm. 5, pp. 1124-1135
-
Clinical Risk Prediction in Patients With Left Ventricular Myocardial Noncompaction
Journal of the American College of Cardiology, Vol. 78, Núm. 7, pp. 643-662
-
Correction to: Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir (Infectious Diseases and Therapy, (2021), 10, 4, (2203-2222), 10.1007/s40121-021-00455-1)
Infectious Diseases and Therapy
-
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial
The Lancet Oncology, Vol. 22, Núm. 6, pp. 801-812
-
Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir
Infectious Diseases and Therapy, Vol. 10, Núm. 4, pp. 2203-2222